LENZ Therapeutics (LENZ) Net Cash Flow (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Net Cash Flow data on file, last reported at -$407000.0 in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 114.11% year-over-year to -$407000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 100.91% increase from a year earlier, with the FY2025 full-year figure at $4.9 million, up 133.0% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$407000.0, down from -$220000.0 in the prior quarter.
• Over the last five years, Net Cash Flow for LENZ reached as high as $165.3 million in Q1 2024 and fell as low as -$191.9 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$20.5 million across 5 years, with a median of -$12.3 million in 2025.
• Across the five-year window, Net Cash Flow tumbled 246.27% in 2022 and jumped 136.67% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at -$8.7 million in 2022, then grew by 11.0% to -$7.7 million in 2023, then sank by 170.99% to -$20.9 million in 2024, then surged by 98.95% to -$220000.0 in 2025, then plunged by 85.0% to -$407000.0 in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$407000.0 in Q1 2026, -$220000.0 in Q4 2025, and -$12.3 million in Q3 2025.